What's Happening?
Jeff Dachis, founder of One Drop, introduced his new venture, One Health Biosensing, at the Frontiers Health conference in Berlin. The company’s first product, FlexCGM, is a continuous glucose monitor
designed to extend the benefits of biosensing beyond diabetes management. Dachis emphasized the transformative potential of continuous glucose monitoring (CGM) in changing health behaviors and outcomes. FlexCGM aims to be accessible and scalable, removing barriers such as cost and clinical gatekeeping. Unlike typical health wearables, FlexCGM is intended for short-term use to train individuals with metabolic conditions like Type 2 diabetes and obesity to modify their behavior. The device is set for FDA submission in 2026, with plans to expand its capabilities to include additional sensors for broader health insights.
Why It's Important?
The introduction of FlexCGM represents a significant shift in the healthcare industry, moving from reactive care to proactive health management. By making biosensing technology more accessible, One Health Biosensing aims to empower individuals to make informed health decisions based on real-time data. This approach could lead to improved health outcomes and reduced healthcare costs, benefiting insurers, employers, and consumers. The focus on unit economics and a low price point could democratize access to advanced health monitoring, potentially transforming how metabolic conditions are managed across the U.S.
What's Next?
FlexCGM is preparing for FDA submission in 2026, which will be a critical step in bringing the product to market. The company plans to expand its sensor capabilities to provide multi-signal insights, enhancing the user experience and product value. This development could lead to broader adoption of biosensing technology, encouraging a shift from episodic care models to continuous health monitoring. Stakeholders such as insurers and employers may play a significant role in funding the device, depending on the specific healthcare outcomes tied to its use.
Beyond the Headlines
The launch of FlexCGM could have ethical and cultural implications, as it challenges traditional healthcare models and promotes self-management of health conditions. The shift from device-centric to decision-centric models may influence how individuals perceive and interact with their health data, fostering a culture of proactive health management. Additionally, the expansion of biosensing technology could raise questions about data privacy and the ethical use of personal health information.
